rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
HWANG TAEYOUNG, Jeonbuk Provincial Maeumsarang Hospital
ClinicalTrials.gov Identifier:
NCT01427088
First received: August 28, 2011
Last updated: February 15, 2015
Last verified: February 2015
  Purpose

This study aims at investigating the neuroplastic potential and the possible factors affecting rehabilitation in chronic schizophrenia patients on stable medication, by investigating the cumulative pattern of serum BDNF representing the neuroplasticity in the brain, through quantitative stimulus such as rTMS.


Condition Intervention
Schizophrenia
Device: CR Technology, TAMAS for repetitive TMS

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Short-Term Response of Serum Brain-Derived Neurotrophic Factor to Repetitive Transcranial Magnetic Stimulation in Patients With Chronic Schizophrenia

Resource links provided by NLM:


Further study details as provided by Jeonbuk Provincial Maeumsarang Hospital:

Primary Outcome Measures:
  • change from baseline of serum BDNF concentration [ Time Frame: baseline-1 week-2 week-4 week ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: August 2011
Study Completion Date: November 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: repetitive TMS
repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
Device: CR Technology, TAMAS for repetitive TMS
repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks

Detailed Description:

Subjects who have been enrolled for this study will take baseline evaluation for sociodemographic data and serum level of BDNF, plasma Prolaction, and magnesium, etc. And then, weekday regular stimulation through rTMS will be applied on DLPFC of brain. After the completion of stimulation for 2 weeks, the change or response of serum BDNF will be analyzed and compared.

  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • duration of illness over 10 years
  • on stable medication, antipsychotics
  • no change on medication within at least 2 weeks
  • Diagnosis of Schizophrenia according to DSM-IV-TR

Exclusion Criteria:

  • left or both-handedness
  • anticonvulsant use
  • lorazepam equivalent over 3 mg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01427088

Locations
Korea, Republic of
Jeonbuk Provincial Maeumsarang Hospital
Wanju, Jeonbuk, Korea, Republic of, 565844
Sponsors and Collaborators
Jeonbuk Provincial Maeumsarang Hospital
Investigators
Principal Investigator: TAEYOUNG HWANG, M.D., M.P.H. Jeonbuk Provincial Maeumsarang Hospital
  More Information

No publications provided

Responsible Party: HWANG TAEYOUNG, Director, Insan Research Center for Psychiatry, Jeonbuk Provincial Maeumsarang Hospital
ClinicalTrials.gov Identifier: NCT01427088     History of Changes
Other Study ID Numbers: rTMS-sBDNF-SPR-2011
Study First Received: August 28, 2011
Last Updated: February 15, 2015
Health Authority: Korea: Institutional Review Board

Keywords provided by Jeonbuk Provincial Maeumsarang Hospital:
rTMS-induced cumulative pattern of sBDNF

Additional relevant MeSH terms:
Schizophrenia
Mental Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on March 30, 2015